新CD分子及其配体的研究

发布时间：2019-02-16 21:27

【摘要】：CD分子在血细胞的分化、增殖、活化、迁移以及机体防御性免疫应答、炎症、凋亡、自身免疫和器官发生等许多生理和病理过程中发挥重要的作用。1982年至2004年间已先后举行了八次人类白细胞分化抗原(HLDA)国际协作组会议，，共命名了339种CD分子及其单克隆抗体(mAb)。CD分子和CD mAb作为一种重要的手段和方法，已广泛地应用于生命科学的研究领域中，包括对基础医学理论以及多种疾病的发病机制、诊断、预防和治疗等临床医学的研究。近年来，随着表达序列标签(EST)大规模筛选系统、cDNA表达文库的构建和筛选、生物质谱和生物信息学等新技术的应用，大量新CD分子被鉴定。在HLDA8中，共有95种新分子及其mAb获得了新的CD命名。其中，在免疫调节如淋巴样组织的发育、细胞增殖、分化和凋亡中发挥重要作用的肿瘤坏死因子超家族和肿瘤坏死因子受体超家族(TNFSF／TNFRSF)成员共获得20个新CD命名；作为一种重要的免疫抑制性受体在免疫细胞和应答中起负调节作用的LAIR-1和LAIR-2也分别获得了新的CD命名，CD305和CD306。本博士课题研究中，制备了TNFSF／TNFRSF 4个新成员的mAb，并投送HLDA8工作组；对国际上多个实验室投送HLDA8的TNFSF／TNFRSF
[Abstract]:CD molecules in the differentiation, proliferation, activation, migration and defensive immune response of the body, inflammation, apoptosis, Autoimmune and organogenesis play an important role in many physiological and pathological processes. Between 1982 and 2004, eight international cooperative meetings on human leukocyte differentiation antigen (HLDA) have been held. As an important means and method, 339 CD molecules and their monoclonal antibody (mAb). CD molecules and CD mAb have been widely used in the field of life science. Including the basic medical theory and the pathogenesis of various diseases, diagnosis, prevention and treatment of clinical medicine research. In recent years, with the large-scale (EST) screening system of expression sequence tags, the construction and screening of cDNA expression library, and the application of new techniques such as biomass spectrometry and bioinformatics, a large number of new CD molecules have been identified. In HLDA8, a total of 95 new molecules and their mAb have obtained new CD nomenclature. The tumor necrosis factor superfamily and tumor necrosis factor receptor superfamily (TNFSF/TNFRSF) members, which play an important role in the development, proliferation, differentiation and apoptosis of immunomodulatory tissues such as lymphoid tissues, have been named 20 new CD. As an important immunosuppressive receptor, LAIR-1 and LAIR-2, which play a negative role in immune cells and responses, have also obtained new CD names, CD305 and CD306., respectively. The mAb, of four new members of TNFSF/TNFRSF and the HLDA8 working group were prepared in this paper. TNFSF/TNFRSF of HLDA8 for several laboratories in the world
【学位授予单位】：第四军医大学
【学位级别】：博士
【学位授予年份】：2006
【分类号】：R392

【相似文献】